If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 7 of 7
SAkuraPEAK: A Phase 1, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Satralizumab in Adult Patients with AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder with Body
Satralizumab in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder
Protocol No
NEURO-GENENTECH-SAKURAPEAK
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study)
Cladribine Tablets in MS with High Disease Activity or Disease Breakthrough
Protocol No
NEURO-EMD-HDA-SWITCH
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendr
Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
Protocol No
NEURO-ROCHE-METEOROID
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-Pegylated Interferon (IFN) or No Disease Mo
Immune Response of Vaccines in Relapsing Forms of MS
Protocol No
NEURO-CELGENE-MS-VACCINE
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)
Protocol No
NEURO-JH-TREAT-MS
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib 100mg B.I.D. Versus Teriflunomide 14mg Q.D. in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-
Remibrutinib vs Teriflunomide in Relapsing MS
Protocol No
NEURO-NOVARTIS-LOU064
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (Nmdar) Or Anti-Leuci
Satralizumab in NMDAR or LGI1 Enchephalitis
Protocol No
NEURO-GENENTECH-CIELO